Recent advances in gene therapy for thalassemia
- PMID: 22923960
- PMCID: PMC3425167
- DOI: 10.4103/0975-7406.99020
Recent advances in gene therapy for thalassemia
Abstract
Thalassemias are genetically transmitted disorders. Depending upon whether the genetic defects or deletion lies in transmission of α or β globin chain gene, thalassemias are classified into α and β-thalassemias. Thus, thalassemias could be cured by introducing or correcting a gene into the hematopoietic compartment or a single stem cell. Initial attempts at gene transfer have proved unsuccessful due to limitations of available gene transfer vectors. The present review described the newer approaches to overcome these limitations, includes the introduction of lentiviral vectors. New approaches have also focused on targeting the specific mutation in the globin genes, correcting the DNA sequence or manipulating the development in DNA translocation and splicing to restore globin chain synthesis. This review mainly discusses the gene therapy strategies for the thalassemias, including the use of lentiviral vectors, generation of induced pluripotent stem (iPS) cells, gene targeting, splice-switching and stop codon readthrough.
Keywords: Gene targeting; lentiviral vectors; splice-switching; stop codon readthrough; thalassemia.
Conflict of interest statement
Figures

Similar articles
-
Gene therapy in thalassemia and hemoglobinopathies.Mediterr J Hematol Infect Dis. 2009 Nov 13;1(1):e2009008. doi: 10.4084/MJHID.2009.008. Mediterr J Hematol Infect Dis. 2009. PMID: 21415990 Free PMC article.
-
Engineered U7 snRNA mediates sustained splicing correction in erythroid cells from β-thalassemia/HbE patients.Biochem Biophys Res Commun. 2018 Apr 30;499(1):86-92. doi: 10.1016/j.bbrc.2018.03.102. Epub 2018 Mar 21. Biochem Biophys Res Commun. 2018. PMID: 29550480
-
Prospects for correction of thalassemia by genetic engineering.Prog Clin Biol Res. 1989;309:141-59. Prog Clin Biol Res. 1989. PMID: 2571166 Review.
-
Genetic defects in the thalassemias.Curr Top Hematol. 1985;5:1-23. Curr Top Hematol. 1985. PMID: 3882340 Review.
-
Enhancement of β-Globin Gene Expression in Thalassemic IVS2-654 Induced Pluripotent Stem Cell-Derived Erythroid Cells by Modified U7 snRNA.Stem Cells Transl Med. 2017 Apr;6(4):1059-1069. doi: 10.1002/sctm.16-0121. Epub 2017 Feb 18. Stem Cells Transl Med. 2017. PMID: 28213976 Free PMC article.
Cited by
-
Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10661-5. doi: 10.1073/pnas.1612075113. Epub 2016 Sep 6. Proc Natl Acad Sci U S A. 2016. PMID: 27601644 Free PMC article.
-
A narrative review of in utero gene therapy: advances, challenges, and future considerations.Transl Pediatr. 2021 May;10(5):1486-1496. doi: 10.21037/tp-20-89. Transl Pediatr. 2021. PMID: 34189107 Free PMC article. Review.
-
CRISPR/Cas9 gene correction of HbH-CS thalassemia-induced pluripotent stem cells.Ann Hematol. 2019 Dec;98(12):2661-2671. doi: 10.1007/s00277-019-03763-2. Epub 2019 Sep 9. Ann Hematol. 2019. PMID: 31495903 Free PMC article.
-
Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.Int J Mol Sci. 2018 Jan 8;19(1):182. doi: 10.3390/ijms19010182. Int J Mol Sci. 2018. PMID: 29316681 Free PMC article. Review.
References
-
- Mohan H. The haematopoietic system. In: Mohan H, Mohan P, Mohan T, editors. The textbook of pathology. 5th ed. New Delhi: Jaypee Brothers Medical Publishers; 2008. pp. 397–402.
-
- Giardini C, Lucarelli G. Bone marrow transplantation in the treatment of thalassemia. Curr Opin Hematol. 1994;1:170–6. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources